Trinity Medical Devices Inc.
Mr. Hollander has over 25 years of professional experience working in medical devices, capital equipment, and pharmaceuticals. With an intense focus on commercialization and sales growth both domestically and internationally, Scott has had direct responsibility for all functional areas including Sales and Marketing, Business Development, HR, Manufacturing, Finance, Logistics, Research and Development, Quality, Healthcare Economics and Government Affairs.
Mr. Hollander started his career as a sales representative with Mallinckrodt Medical in Jacksonville, FL. Over his 14 year career with Mallinckrodt he held positions of increasing responsibility including Regional Manager, Market Manager, Director of Marketing, Sr. Director of Global Strategy and Commercialization, Sr. Director of Business Development and VP of Sales, Marketing and Commercial Development. During his tenure at Mallinckrodt, Scott grew numerous line of business to a #1 position and completed more than 20 business development transactions.
Mr. Hollander has held positions of COO and CEO at both private and publically traded companies. Mr. Hollander served as COO/Head of North America for Bracco Diagnostics where he grew company revenue through successfully negotiating and being awarded four major GPO contracts, a focused effort on new customers, and increasing compliance at existing accounts. He led the organization to a #1 position in three key product categories, positions they still hold to this day. Mr. Hollander also participated in Bracco’s strategic acquisition and integration of E-Z-EM, a leading manufacturer of contrast agents for gastrointestinal radiology.
In 2008 Mr. Hollander joined Otsuka Pharmaceuticals as the VP of Business Development. Mr. Hollander completed the acquisition of Interpharma in Prague, Czech Republic and was named President and Chief Executive Officer. During the next 5 years Mr. Hollander built and transitioned Interpharma from a post-communist manufacturing entity to a company that developed and gained FDA approval for product invented and developed in Prague. This was the first time in Otsuka’s history that a product was invented, developed, and approved outside of Japan.
Mr. Hollander was the President and CEO of Echo Therapeutics from 2015 through September 2016. During his time at Echo he rehired the administrative and research development personnel, restarted development activities and refocused the company’s strategy focusing on a diabetic application for the company’s non-invasive glucose monitoring device.
Mr. Hollander holds a BS in Political Science from Alfred University and a MBA in Business and Health Services Management from the Olin School of Business, Washington University, St. Louis, MO.